Bio-Techne Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US09073M1045
USD
63.54
0.59 (0.94%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Bio-Techne Corp. stock-summary
stock-summary
Bio-Techne Corp.
Pharmaceuticals & Biotechnology
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences reporting segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology community. The Protein Sciences segment also provides an array of platforms useful in various areas of protein analysis. The Diagnostics and Genomics reporting segment provides blood chemistry and blood gas quality controls, hematology instrument controls, diagnostics immunoassays and other bulk and custom reagents for the in vitro diagnostic market.
Company Coordinates stock-summary
Company Details
614 McKinley Pl NE , MINNEAPOLIS MN : 55413-2610
stock-summary
Tel: 1 612 37988541 646 2771266
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 135 Schemes (52.11%)

Foreign Institutions

Held by 290 Foreign Institutions (18.37%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Robert Baumgartner
Independent Chairman of the Board
Mr. Charles Kummeth
President, Chief Executive Officer, Director
Ms. Julie Bushman
Independent Director
Mr. John Higgins
Independent Director
Dr. Joseph Keegan
Independent Director
Dr. Roeland Nusse
Independent Director
Dr. Alpna Seth
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
317 Million
(Quarterly Results - Jun 2025)
Net Profit:
-18 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 8,417 Million (Small Cap)

stock-summary
P/E

37.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

44.91%

stock-summary
Debt Equity

0.10

stock-summary
Return on Equity

11.21%

stock-summary
Price to Book

4.39